Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis
© 2023. The Author(s)..
Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS-/-) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS-/- mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS-/- livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cell death & disease - 14(2023), 8 vom: 10. Aug., Seite 514 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
CL2T97X0V0 |
|---|
| Anmerkungen: |
Date Completed 15.08.2023 Date Revised 17.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41419-023-06029-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36062720X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36062720X | ||
| 003 | DE-627 | ||
| 005 | 20231226083421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41419-023-06029-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM36062720X | ||
| 035 | |a (NLM)37563155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Kang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.08.2023 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS-/-) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS-/- mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS-/- livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Carbon Tetrachloride |2 NLM | |
| 650 | 7 | |a CL2T97X0V0 |2 NLM | |
| 650 | 7 | |a Nras protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 700 | 1 | |a Hao, Fengjie |e verfasserin |4 aut | |
| 700 | 1 | |a Medrano-Garcia, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chaobo |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Feifei |e verfasserin |4 aut | |
| 700 | 1 | |a Morán-Blanco, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Perales, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Ruiz, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Peligros, María Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Vaquero, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Bañares, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Del Moral, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Regueiro, José R |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Naves, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Mohamed Ramadan |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego-Durán, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Maya, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Ampuero, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gómez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert-Ramos, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Guixé-Muntet, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Iglesias, Anabel |e verfasserin |4 aut | |
| 700 | 1 | |a Gracia-Sancho, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Coll, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Graupera, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Ginès, Pere |e verfasserin |4 aut | |
| 700 | 1 | |a Ciudin, Andreea |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera-Esteban, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Pericàs, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a Frutos, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Molina, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Herranz, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Ávila, Matías A |e verfasserin |4 aut | |
| 700 | 1 | |a Nevzorova, Yulia A |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Malavé, Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Cubero, Francisco Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell death & disease |d 2010 |g 14(2023), 8 vom: 10. Aug., Seite 514 |w (DE-627)NLM202030881 |x 2041-4889 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:8 |g day:10 |g month:08 |g pages:514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41419-023-06029-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 8 |b 10 |c 08 |h 514 | ||